{"filings":[{"id":759197,"accession_number":"0001193125-26-249684","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2026-06-01T10:56:36+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"IN8bio enters new ATM equity facility with JonesTrading, terminates prior Cantor agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Capital on Demand Sales Agreement with JonesTrading for at-the-market offerings of common stock.","Agent receives 3.0% commission on gross proceeds; no obligation to sell; company may terminate on 10 days' notice.","Terminated prior Controlled Equity Offering Sales Agreement with Cantor Fitzgerald effective May 29, 2026, with no penalties.","New ATM program registered under Form S-3 (File No. 333-291393); shares sold via Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95114,"accession_number":"0001193125-26-212128","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","5.02","5.07","9.01"],"status":"ready","headline":"IN8bio Q1 2026 net loss $5.1M; GBM mPFS improved 97% vs SOC; cash $21.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.1M ($0.26/sh) vs $5.6M ($2.16/sh) in Q1 2025; cash $21.9M up from $11.9M.","GBM Phase 1/2: median PFS 13.0 months (repeat dose) vs 6.6 SOC (+97%); mOS still climbing at 17.2+ months.","INB-619 TCE platform progressing toward IND; initial animal data expected in 2026.","Anticipated FDA guidance on GBM regulatory pathway in 2H26; updated mOS data at ASCO 2026.","R&D expenses $2.6M (down from $3.0M) on lower INB-400 clinical activity."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107952,"accession_number":"0001193125-26-104144","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IN8bio reports FY2025 net loss $19.4M; GBM trial shows 97% PFS improvement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.4M ($4.44/share) vs $30.4M ($17.05/share) prior year; cash $27.1M vs $11.1M year-end 2024.","Updated GBM data: mPFS 13.0 months for DRI patients vs 6.6 months SOC (+97%); mOS not yet reached at 17.2+ months.","Closed initial $20.1M of $40.2M private placement; net proceeds $18.5M extend cash runway into H1 2027.","Kate Rochlin promoted to President and COO in February 2026.","Anticipates FDA guidance on regulatory pathway for GBM program by H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107951,"accession_number":"0001193125-26-082539","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IN8bio director Alan Roemer resigns; Jeremy Graff appointed Interim Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan S. Roemer resigned as director and from Audit and Compensation Committees, effective Feb 28, 2026.","Resignation not due to any disagreement with company, management, or board on operations, policies, or practices.","Board appointed Jeremy Graff, an independent director, as Interim Chair of the Board effective Feb 28, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107950,"accession_number":"0001193125-26-041975","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IN8bio appoints COO Kate Rochlin as President, effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kate Rochlin, current COO, assumes additional role of President effective Feb. 4, 2026.","Dr. Rochlin will continue serving as Chief Operating Officer of IN8bio.","Appointment made by Board on Feb. 4, 2026; no other executive changes.","No family relationships or transactions requiring disclosure under Regulation S-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124367,"accession_number":"0001193125-25-327097","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"IN8bio enters $20.1M private placement with potential second $20.1M tranche tied to INB-619 milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing: 5,127,029 shares at $1.38 and 9,452,677 pre-funded warrants for ~$20.1M gross.","Second closing up to 14.6M shares/warrants (~$20.1M) conditional on INB-619 milestone and stock price hitting $2.76 or waiver.","Investors granted pre-emptive rights to participate in subsequent equity financings up to 200% of their investment.","Company to file resale registration statement within 30 days of each closing, with liquidated damages for delays.","Private placement exempt from registration; purchasers are qualified institutional buyers or accredited investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124366,"accession_number":"0001193125-25-292057","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"IN8bio presents GBM trial data: mPFS 13.0 mo vs 6.6 SOC; mOS not reached at 16.4+ mo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 INB-200 and Phase 2 INB-400 data presented at SNO 2025 for newly diagnosed glioblastoma.","14 patients received repeated DeltEx DRI gamma-delta T cells; mPFS 13.0 months vs 6.6 for SOC (n=10).","Median OS not yet reached for DRI patients at 16.4+ months as of Oct 31, 2025; SOC mOS 11.0 months.","17 patients treated across both trials; 10 additional SOC-only patients monitored for comparison."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124365,"accession_number":"0001193125-25-269442","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IN8bio Q3 net loss $3.9M ($0.85/share); cash $10.7M; INB-619/100 updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.9M in Q3 2025 vs $7.1M in Q3 2024; basic and diluted EPS -$0.85 vs -$4.49.","R&D expenses $2.1M (down from $3.3M); G&A $1.9M (down from $2.7M) due to cost-saving measures.","Cash $10.7M as of Sep 30, 2025, up from $4.0M year-over-year.","INB-619 preclinical data at ACR showed B cell elimination similar to blinatumomab/mosunetuzumab with minimal cytokine release.","INB-100 Phase 1 trial expanded to The Ohio State University to accelerate enrollment; updated GBM data planned at SNO Nov 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124364,"accession_number":"0001193125-25-250756","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio presents INB-619 preclinical data at ACR showing deep B cell depletion with minimal cytokine release","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["INB-619 achieved complete B cell depletion in SLE donor models, equivalent to FDA-approved blinatumomab and mosunetuzumab.","INB-619 showed minimal IL-6 secretion at concentrations far lower than marketed TCEs, suggesting reduced CRS risk.","INB-619 selectively expanded γδ T cells without activating αβ T cells, supporting a safer safety profile.","Data presented at 2025 ACR Convergence; INB-619 is a potential first-in-class pan-γδ T cell engager targeting CD19."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141034,"accession_number":"0000950170-25-104986","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IN8bio reports Q2 net loss of $5.1M; 4-year PFS milestone in glioblastoma trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.1M ($1.24/sh) vs $8.6M ($5.51/sh) in Q2 2024; R&D expenses down to $2.5M from $5.2M.","Cash $13.2M as of June 30, 2025 (up from $10.2M year ago); runway extended into June 2026.","INB-200 trial patient surpasses 4 years without progression; mPFS 16.1 months for multi-dose patients (standard of care 6.9 months).","Preclinical data at ASGCT 2025: INB-619 achieves complete B cell depletion in lupus samples without significant inflammatory cytokines.","Received Host Region USA East Abstract Award at ISCT 2025 for DeltEx manufacturing platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158822,"accession_number":"0001193125-25-152037","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"IN8bio regains compliance with Nasdaq minimum bid price rule; matter closed.","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received formal Nasdaq notification on June 24, 2025, confirming compliance with minimum bid price of $1.00 per share.","Previously non-compliant with Listing Rule 5550(a)(2); compliance now regained and matter closed.","No further action required; stock continues trading on Nasdaq under ticker INAB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158821,"accession_number":"0001193125-25-134487","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"IN8bio to effect 1-for-30 reverse stock split effective June 5, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-30 ratio; effective 5:00 p.m. ET on June 5, 2025.","Shares outstanding will reduce from ~103.3M to ~3.4M (subject to fractional share cash-out).","Stock begins trading on Nasdaq on split-adjusted basis June 6, 2025; new CUSIP 45674E208.","Proportionate adjustments to stock options, warrants, and equity plan reserves; no fractional shares issued.","Charter Amendment filed as Exhibit 3.1; authorized by stockholders on May 8, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158820,"accession_number":"0001193125-25-132783","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio Phase 1 INB-200 shows mPFS 16.1 months, more than double SOC in GBM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median PFS in repeated-dose patients reached 16.1 months vs 6.9 months historical SOC Stupp protocol.","Four patients (40%) receiving repeated doses remain alive and progression-free for median over two years.","No dose-limiting toxicities, CRS, or ICANS observed; most adverse events Grade 1-2.","Phase 2 INB-400 trial shows preliminary mPFS of 10.8 months; additional data expected late 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158819,"accession_number":"0001193125-25-116901","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"IN8bio shareholders approve reverse stock split; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split proposal approved with 43.6M votes for, 3.2M against, 90k abstain.","Three directors elected: Emily Fairbairn, Jeremy Graff, Luba Greenwood; each received >30M votes for.","Ratification of CohnReznick LLP as auditor for FY2025 passed with 45.0M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158818,"accession_number":"0000950170-25-065603","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IN8bio reports Q1 2025 net loss of $5.6M; INB-100 shows 100% AML relapse-free at 20.1 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.6M ($0.07/sh) vs. $8.6M ($0.20/sh) prior year; cash $11.9M as of March 31, 2025.","Phase 1 INB-100 data: 100% AML patients relapse-free at median 20.1 months follow-up; no CRS/ICANs.","Presented INB-600 TCE platform at AACR 2025 showing picomolar potency and minimal cytokine release.","Upcoming oral presentation at ASCO 2025 for INB-200 in glioblastoma (May 30, 2025).","Raised ~$4.1M net from ATM and warrant exercises in Q1 2025; additional $1.9M gross in April 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158817,"accession_number":"0001193125-25-098599","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio Announces Preclinical Data from Gamma-Delta T Cell Engager Platform at AACR 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["INB-619 (CD19) and INB-633 (CD33) showed potent dose-related killing of leukemia cells at low picomolar concentrations in preclinical studies.","Platform activated and expanded both Vδ1+ and Vδ2+ T cell subsets, addressing reduced cell counts in cancer patients.","Minimal secretion of cytokines IL-6, IL-10, IL-17a suggests lower risk of cytokine release syndrome versus conventional CD3 TCEs.","CEO William Ho highlighted potential for off-the-shelf, scalable platform to target cancers and autoimmune diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158816,"accession_number":"0001193125-25-098597","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"IN8bio raises ~$1.9M via warrant exercises/exchanges at reduced prices; Series B warrant strike cut to $0.45","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrant exercises for 7,178,934 Series A and 2,142,147 Series B shares at $0.1844 (insiders) or $0.1784 (others) per share.","Warrant exchanges: 656,208 Series A and 574,241 Series B surrendered for pre-funded warrants at $0.0001 exercise price.","Total expected gross proceeds of ~$1.9 million from the transactions.","Series B warrant exercise price amended from $1.50 to $0.45 for holders not participating in exercises.","Transactions must close by May 2, 2025; warrants unexercised by then will terminate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177226,"accession_number":"0000950170-25-038728","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IN8bio reports Q4 2024 net loss $6.2M; cash $11.1M as of Dec 31; clinical updates on INB-100/200/400","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $6.2M ($0.08/share) vs $7.6M ($0.22/share) in Q4 2023; full-year net loss $30.4M vs $30.0M.","Cash $11.1M as of Dec 31, 2024; plus $4.1M net proceeds from ATM/warrant exercises in Feb 2025, extending runway into March 2026.","INB-100 Phase 1: 100% of treated AML patients relapse-free as of Jan 17, 2025; no CRS/ICANS; enrollment expansion ongoing.","INB-200: majority of patients exceeded expected PFS; one IDH-mutant patient progression-free for 40.5 months as of Oct 2024.","INB-400 Phase 2 enrollment paused; seeking partnerships; introduced INB-600 platform (INB-619 TCE targeting CD19) with preclinical data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177225,"accession_number":"0001193125-25-047244","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IN8bio board member Travis Whitfill resigns effective May 9, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Travis Whitfill notified IN8bio board of his resignation on March 4, 2025.","Resignation effective May 9, 2025; not due to any disagreement with the company.","Whitfill also resigned from all board committees.","No replacement or further board changes announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177224,"accession_number":"0001193125-25-043564","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio unveils gamma-delta T cell engager platform with lead candidate INB-619","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["INB-600 platform expands both Vd1+ and Vd2+ T cells; lead INB-619 targets CD19 for B-cell cancers and autoimmune diseases.","Preclinical data: up to 450-fold T cell expansion, rapid and sustained B-cell depletion with target cells eradicated.","Natural lower IL-6 secretion may reduce risk of CRS and neurotoxicity vs. CAR-T and traditional TCEs.","CEO cites unmet need for deep B-cell depletion with improved safety; plans to seek partners for IND-enabling trials.","No CRS or neurotoxicities observed to date in IN8bio's ongoing gamma-delta T cell clinical programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177223,"accession_number":"0001193125-25-024005","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio Phase 1 INB-100: 100% AML remission at median 20.1 months, 100% 1-year PFS/OS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 9 AML patients remain in complete remission; median follow-up 20.1 months, longest >3 years.","One-year PFS/OS 100% vs historical controls (CIBMTR PFS 67.8%, OS 74.7%).","No cytokine release syndrome or neurotoxicity observed; manageable GvHD in line with historical data.","Patients median age 68, high-risk, including prior CAR-T failures; therapy well-tolerated.","Company to host conference call today at 8:30am ET to discuss data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177222,"accession_number":"0001193125-25-022711","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["3.01","5.08"],"status":"ready","headline":"IN8bio receives Nasdaq bid-price extension to Aug 4, 2025; stock moves to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted IN8bio until Aug 4, 2025 to achieve $1.00 closing bid for 10 consecutive days.","Common stock transferred from Nasdaq Global Market to Nasdaq Capital Market effective Feb 7, 2025.","Company may consider reverse stock split to regain compliance if needed.","2025 Annual Meeting set for May 8; record date March 12, 2025.","Stockholder proposals and director nominations due Feb 17, 2025; universal proxy notice due March 9."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193989,"accession_number":"0001193125-24-273953","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio reports 100% AML CR rate with INB-100 at ASH; no relapses after median 19.7 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of AML patients (n=10) remain in complete remission after median 19.7 months follow-up; no relapses or new deaths as of Sept 30, 2024.","INB-100 shows durable in vivo expansion and persistence of allogeneic gamma-delta T cells at 365 days post single dose.","No CRS, neurotoxicity (ICANS), or dose-limiting toxicities observed; low-grade GvHD steroid-responsive in 60% of patients.","Expansion cohort enrollment ongoing at DL2 (RP2D); updated data expected first half 2025.","Three patients in CR >3 years, one progression-free >4 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193988,"accession_number":"0001193125-24-264714","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio Phase 1 INB-200 data: 50% of multi-dose patients alive beyond expected median OS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["50% of multi-dose patients (n=10) alive beyond expected median OS from Stupp regimen; none in single-dose group (n=3).","Biopsy confirmed gamma-delta T cell persistence in brain tumor microenvironment in two patients post-treatment.","Median PFS in repeat-dose patients increased 79% vs. 6.9 months for Stupp regimen.","No treatment-related serious adverse events, cytokine release syndrome, or neurotoxicity reported.","One IDH-mutant glioma patient remains alive and progression-free at 40.5 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193987,"accession_number":"0000950170-24-125526","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IN8bio Q3 net loss $7.1M; cash $4.0M; closes $11.6M placement; INB-100/200 updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.1M ($0.15 per share) vs $7.2M loss ($0.23) in Q3 2023.","Cash $4.0M at Sept 30; closed Oct private placement for $11.6M net proceeds, extending runway into Q1 2026.","R&D $3.3M (-13% YoY), G&A $2.7M (-21% YoY); severance charges $1.1M from workforce reduction.","All AML patients in INB-100 remain in CR; FDA provided registrational path; expansion to ~25 patients planned.","Suspended INB-400 Phase 2 enrollment for newly diagnosed GBM; monitoring continues at SNO and ASH meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193986,"accession_number":"0001193125-24-230283","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"IN8bio raises $12.4M in private placement; amends Series A warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$12.4M from sale of units at $0.3950 per unit; closing expected Oct 4, 2024.","Units consist of common stock or pre-funded warrants plus Series C warrants (exercise price $0.27, 3-year term).","Series A warrants amended: exercise price reduced from $1.25 to $0.45, term extended by one year from closing.","Company to file resale registration statement within 30 days of closing.","Funds expected to support operating plan into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210326,"accession_number":"0001193125-24-217229","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IN8bio CMO Trishna Goswami steps down effective Sept 6, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Goswami and company mutually agreed to her departure as Chief Medical Officer.","Separation agreement provides two months' base salary cash severance.","Agreement includes general release, non-disparagement, confidentiality, and cooperation covenants.","Full separation agreement to be filed as exhibit to Q3 2024 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210325,"accession_number":"0001193125-24-215154","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IN8bio cuts CEO Ho's salary to $544,680; other execs also reduced, severance enhanced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO William Ho salary cut from $612,000 to $544,680; Trishna Goswami from $495,000 to $440,550 effective Sept 1, 2024.","Amendments cover five executives: Ho, Goswami, Lamb, McCall, Rochlin as part of previously announced workforce reduction.","Severance improved: for Ho, 18 months base (greater of current or at termination); for Goswami, 12 months base.","Change-of-control severance: Ho gets 18 months base plus 150% target bonus; Goswami gets 12 months base plus 100% bonus.","Salary reductions cannot be used as grounds for 'good reason' resignation under employment agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210324,"accession_number":"0001193125-24-213132","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"IN8bio cuts workforce 49%, suspends GBM trial to focus on AML therapy INB-100","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduced from 37 to 19 FTEs; exec/board take 11% cash compensation cut.","One-time severance costs of ~$0.3M expected in Q3 2024.","INB-100 Phase 1 AML trial shows 100% relapse-free survival at median 18.7 months follow-up; expansion cohort targeting ~25 patients by H1 2025.","Enrollment suspended in INB-400 Phase 2 GBM trial; IN8bio will monitor existing patients and explore partnerships.","Company exploring other strategic alternatives to preserve cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210323,"accession_number":"0001193125-24-198411","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio reports 100% AML remission with INB-100; FDA guidance for registrational trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of AML patients in Phase 1 trial remain in complete remission; all relapse-free beyond one year.","Received FDA guidance for registrational trial of INB-100 in AML; IND submission planned Q1 2025.","INB-200 for GBM shows prolonged survival in higher dose cohorts; one MGMT-unmethylated patient in remission >1 year.","No new relapses since May 15, 2024; safety manageable with no significant cell therapy-related toxicities.","INB-400 Phase 2 trial for front-line GBM actively enrolling at multiple US sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210322,"accession_number":"0000950170-24-093932","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","3.01","9.01"],"status":"ready","headline":"IN8bio receives Nasdaq minimum bid price deficiency notice; Q2 net loss $8.6M, cash $10.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified IN8bio on Aug 6, 2024 that bid price closed below $1.00 for 31 consecutive days; 180-day compliance period to Feb 3, 2025.","Q2 2024 net loss of $8.6M ($0.19 per share) vs net loss of $7.7M ($0.27) in Q2 2023.","Cash and cash equivalents totaled $10.2M as of June 30, 2024, down from $21.3M at Dec 31, 2023.","Phase 1 INB-100 data: 100% 1-year complete remission in evaluable patients; two patients relapse-free over 3.5 years.","Phase 1 INB-200: 92% of GBM patients exceeded median PFS of 7 months; no cell therapy-related toxicities observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228639,"accession_number":"0001193125-24-160703","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"IN8bio Phase 1 INB-100 shows 100% durable CR at 1 year in leukemia patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of evaluable leukemia patients (n=10) remain in durable CR at 1 year as of May 31, 2024.","First allogeneic cellular therapy to show in vivo gamma-delta T cell expansion/persistence at 365 days.","Favorable safety: no DLTs, CRS, neurotoxicity, or ICANS observed.","Two patients relapse-free >3.5 years; third nearing 3 years post-transplant.","Trial expanded at Dose Level 2; FDA Type B meeting planned this summer for potential registrational path."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228638,"accession_number":"0001193125-24-152493","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio reports 92% of INB-200 patients exceed 7-month PFS in Phase 1 GBM study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["92% of evaluable patients exceeded median PFS of 7 months (Stupp regimen); median follow-up 11.7 months.","One Cohort 2 patient alive and progression-free at 34.9+ months; IDH-mutant glioma case.","No CRS, ICANS, or dose-limiting toxicities; common AEs were Grade 1-2 related to TMZ.","Phase 2 INB-400 now dosing newly diagnosed GBM patients with up to six infusions.","Radiographic improvements included resolution of midline shift and 36% lesion decrease in one patient."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228637,"accession_number":"0000950170-24-056866","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IN8bio reports Q1 2024 net loss $8.6M, cash $13.0M; first patient dosed in INB-400 Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $8.6M ($0.20/sh) vs $7.5M ($0.30/sh) in Q1 2023; R&D $4.9M, G&A $3.7M.","Cash $13.0M at March 31, 2024, down from $21.3M at December 31, 2023.","First patient dosed in Phase 2 autologous arm of INB-400 for newly diagnosed GBM.","Potential IND submission for INB-100 Phase 2 registrational trial in 2024 in AML/MDS.","Preclinical nsCAR data at AACR 2024 targeting CD33/CD123 for AML while sparing healthy cells."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247286,"accession_number":"0000950170-24-031478","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IN8bio reports Q4 2023 net loss of $7.6M and cash of $21.3M; highlights positive clinical data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $7.6M ($0.22 per share) vs Q4 2022 net loss $7.8M ($0.32 per share).","Full-year 2023 net loss $30.0M ($1.00 per share); R&D expenses increased to $16.8M.","Cash $21.3M as of Dec 31, 2023 vs $18.2M a year earlier; private placement extended runway into 1Q 2025.","100% of evaluable leukemia patients (n=10) in INB-100 Phase 1 remained in remission as of Nov 3, 2023.","Appointed Dr. Corinne Epperly, M.D., M.P.H. to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264717,"accession_number":"0001193125-23-292706","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"IN8bio raises $14.4M in private placement; potential total up to $46.9M via warrant exercises","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial gross proceeds of $14.4M from selling 11.8M units at $1.22/unit; extends cash runway into 2025.","Investors get Series A warrants ($1.25 strike) exercisable upon INB-100 11-month data announcement for up to $14.8M additional.","Series B warrants ($1.50 strike) redeemable upon 22-month data; potential $17.7M extra if all exercised.","Pre-funded warrants at $0.0001 exercise price included; Cantor Fitzgerald acted as sole placement agent.","Proceeds to fund clinical development of gamma-delta T cell therapies and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264716,"accession_number":"0001193125-23-292121","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"IN8bio reports 100% of evaluable patients in Phase 1 INB-100 trial remain in complete remission","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 evaluable patients alive, progression-free, and in durable CR as of Nov 3, 2023; 6 relapse-free for over 1 year.","No dose-limiting toxicities observed; low-grade acute GVHD in 60% of patients.","Gamma-delta T cells expanded and persisted >365 days post single dose; dose response shows 48.9x greater at day 60 for DL 2 vs HSCT alone.","Two patients progression-free for over 3 years; individual follow-up ranges 4.9 to 42.7 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264715,"accession_number":"0001193125-23-290707","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"IN8bio appoints Dr. Corinne Epperly to Board, adopts amended bylaws","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 8 directors; Dr. Epperly appointed as Class II director effective Dec 6, 2023, term through 2026 annual meeting.","Dr. Epperly to serve on Compensation and Science & Technology Committees; former COO of Cargo Therapeutics and SVP at Iovance.","Bylaws amended to comply with universal proxy rules (Rule 14a-19), enhance stockholder nominee disclosures, and adopt DGCL updates.","Non-employee director compensation policy updated Dec 5, 2023: annual cash retainer $40k, initial option grant 54,800 shares, annual grant 27,400 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264714,"accession_number":"0001193125-23-280283","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio's INB-200 Phase 1 trial: all patients completing doses exceed 7-month PFS; one remains alive at 28.5+ months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All ten patients who completed mandated doses exceeded progression-free survival (PFS) of 7 months, exceeding standard-of-care median PFS of 4-7 months.","One patient with IDH-mutant glioma remains alive and progression-free at 28.5+ months (median PFS for IDH-mutant patients in NEJM control arm: 11.1 months).","No treatment-related serious adverse events, dose-limiting toxicities, cytokine release syndrome, infusion reactions, or ICANS reported.","Three dosing cohorts: Cohort 1 (1 dose, 3 pts), Cohort 2 (3 doses, 4 pts), Cohort 3 (6 doses, 3 pts); additional enrollment in Cohort 3 expected to complete in 2023.","Preserved gamma-delta T cells found in relapsed tumor 148 days after initial DRI infusion, indicating durability of cells."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264713,"accession_number":"0000950170-23-061992","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IN8bio Q3 net loss $7.2M; cash $12.9M; clinical progress on gamma-delta T cell trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.2M ($0.23/sh) vs $7.4M ($0.34/sh) in Q3 2022; R&D $3.8M, G&A $3.4M.","Cash $12.9M at Sep 30, 2023, down from $17.0M at Jun 30, 2023.","Phase 1 INB-100 dose escalation completed; ASH data presentation Dec 11, 2023.","Phase 2 INB-400 in newly diagnosed GBM enrollment initiated; SNO poster Nov 17.","Phase 1 INB-200 updated data at SNO Nov 17; Cohort 3 enrollment ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264712,"accession_number":"0001193125-23-254659","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio starts Phase 2 GBM trial (INB-400) and completes Phase 1 dose escalation (INB-100)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment open for Phase 2 trial of INB-400 in newly diagnosed GBM; plans ~40 patients in Arm A; primary endpoint 12-month OS.","Dose escalation phase of Phase 1 INB-100 trial in leukemia closed; clinical update expected at ASH Dec 9-12, 2023.","As of April 2023, 100% of evaluable patients (n=7) on INB-100 in durable complete remission; one patient progression-free >3 years.","First activated sites for INB-400: University of Louisville and Cleveland Clinic; INB-400 received FDA Orphan Drug Designation April 2023.","R&D Day held October 12, 2023; webcast available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281948,"accession_number":"0000950170-23-041481","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IN8bio reports Q2 2023 net loss of $7.7M, cash $17.0M; positive INB-200 Phase 1 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.7M ($0.27/sh) vs $7.2M ($0.38/sh) in Q2 2022; R&D expense $4.1M, G&A $3.6M.","Cash $17.0M as of June 30, 2023, up from $10.9M on March 31, 2023.","INB-200 Phase 1 data: 100% of treated GBM patients (n=8) exceeded median PFS; enrollment completion expected in 2023.","INB-400 Phase 2 trial in GBM on track to initiate enrollment in H2 2023; primary endpoint overall survival.","R&D day scheduled for October 12, 2023 in New York City; preclinical ovarian cancer data presented at ASGCT."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300961,"accession_number":"0001193125-23-169011","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"IN8bio stockholders elect directors, approve 2023 equity plan and auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Peter Brandt and Travis Whitfill elected as directors; votes for 16.1M and 12.6M, respectively.","Stockholders ratified Amended and Restated 2023 Equity Incentive Plan with 15.8M for, 717k against, 25.9k abstain.","CohnReznick LLP ratified as independent auditor for FY 2023: 18.96M for, 43.6k against, 36.8k abstain.","Annual meeting held June 15, 2023; all proposals approved as recommended by board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300960,"accession_number":"0001193125-23-160340","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio Phase 1 INB-200 data shows 100% of GBM patients exceed historical median PFS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% (8/8) patients exceeded historical median PFS of 4-7 months; two patients from three-dose cohort remain progression-free at 23.5 and 19.4 months.","No treatment-related SAEs, DLTs, CRS, or ICANS reported; common TEAEs mild and linked to temozolomide.","Cohort 1 PFS ranged 7.4–11.9 months; Cohort 3 first patient had 7.1 months PFS with no brain progression.","Company on track to complete Phase 1 enrollment in 2023; further updates expected later this year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300959,"accession_number":"0001193125-23-146576","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio preclinical data shows DeltEx gamma-delta T cells kill ovarian cancer cells, including resistant lines","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Data presented at ASGCT 2023 demonstrate DeltEx T cells target and kill ovarian cancer cells even in platinum-resistant lines.","Temozolomide (TMZ) combined with PARP inhibitors synergistically increased NKG2D-L expression, enhancing tumor cell visibility to gamma-delta T cells.","CEO William Ho highlighted synergy of gamma-delta T cells with chemotherapy for solid tumors beyond the brain.","CSO Lawrence Lamb noted potential for INB-400 in ovarian cancer and other solid tumors; further evaluation planned.","Preclinical proof-of-concept supports DeltEx Drug Resistance Immunotherapy (DeltEx DRI) platform in challenging indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300958,"accession_number":"0000950170-23-021505","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IN8bio Q1 net loss $7.5M, cash $10.9M; INB-100 achieves 100% CR in leukemia trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $7.5M ($0.30/sh); cash $10.9M at Mar 31; raised $9.9M via ATM after quarter end.","INB-100 Phase 1: 100% complete remissions in 7 evaluable leukemia patients; all alive; selected RP2D.","FDA orphan drug designation for INB-400 and INB-410 for malignant gliomas, including GBM.","INB-200 Phase 1 data selected for oral abstract at ASCO 2023; new preclinical data in ovarian cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300957,"accession_number":"0001193125-23-130432","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IN8bio appoints Jeremy Graff, Ph.D. as Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from six to seven directors; Graff appointed effective May 1, 2023, term expiring at 2025 annual meeting.","Graff currently serves as Chief Scientific Officer of IMV, Inc.; previously President/CSO of Biothera Pharmaceuticals and Chief Development Officer at HiberCell.","Graff will serve on Nominating & Corporate Governance Committee and chair the Science and Technology Committee.","Compensation follows standard non-employee director policy; company entered into standard indemnification agreement with Graff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300956,"accession_number":"0001193125-23-111832","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-04-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"IN8bio reports 100% complete remission in INB-100 Phase 1 leukemia trial; RP2D selected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of evaluable patients (n=7) in durable CR; one patient progression-free beyond 3 years.","Gamma-delta T cells expanded 82.9x at Dose Level 2 vs. standard haploidentical HSCT at 60 days.","Dose Level 2 selected as recommended Phase 2 dose based on safety, tolerability, and expansion data.","No dose-limiting toxicities observed; all GvHD low-grade and steroid-responsive.","Conference call today at 10 a.m. ET; updated data expected at future medical meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300955,"accession_number":"0001193125-23-103616","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IN8bio announces positive preclinical data for nsCAR platform and launches INB-330 program at AACR 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["nsCAR platform showed ability to target cancer cells while sparing healthy tissue; ns19CAR killed 80% of leukemia cells vs 5% of healthy B cells.","Launched INB-330 program targeting CD33 in AML; ns33CAR demonstrated anti-leukemic activity against AML, B-ALL, and CML cell lines.","Data presented at AACR Annual Meeting 2023; management highlights potential to address previously 'undruggable' targets.","Company seeks potential partners for further evaluation of nsCAR platform with additional targets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320840,"accession_number":"0000950170-23-010956","cik":1740279,"company_name":"IN8BIO, INC.","ticker":"INAB","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IN8bio reports FY2022 net loss $28.5M; cash $18.2M; clinical data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $18.2M at Dec 31, 2022, down from $37.0M a year earlier; R&D spend $14.1M (FY2022) vs $7.3M.","Net loss $28.5M ($1.36/share) for FY2022 vs $14.7M ($1.47/share) in FY2021; Q4 loss $7.8M ($0.32/share).","INB-100 leukemia patients maintain durable complete responses beyond 18 months, up to 2.7 years in Phase 1.","INB-200 GBM trial: two patients progression-free at 1.5 and 1.2 years; enrolling Cohort 3; updated data mid-2023.","FDA cleared IND for INB-400 Phase 2 trial in GBM; enrollment expected H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17232404.583333332,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-30T23:59:59+00:00|320840"}